Researchers have developed new blood tests to help diagnose Alzheimer’s disease more quickly and accurately, as it can be challenging to differentiate between memory problems caused by Alzheimer’s and other conditions. These tests detect signs of Alzheimer’s in the blood, such as beta-amyloid accumulation. While some tests are accurate, others are less reliable. Demand for early diagnosis of Alzheimer’s is increasing, but there is limited data on which tests are most effective. New drugs like Leqembi and Kisunla can slow symptoms in the early stages, but confirming eligibility for these treatments can be challenging.
A study in Sweden found that blood tests were more accurate at diagnosing Alzheimer’s compared to traditional cognitive exams. The most reliable blood tests measure p-tau217, a form of tau protein that correlates with plaque buildup in the brain. Companies like ALZpath, Roche, Eli Lilly, and C2N Diagnostics are developing p-tau217 tests. The Alzheimer’s Association recommends using blood tests with over 90% accuracy rates, especially for people with memory problems.
While these blood tests show promise, they are currently only recommended for individuals with symptoms, not those without symptoms but concerns about Alzheimer’s. Early detection is crucial, as amyloid buildup can start years before symptoms appear. The FDA has not yet approved these tests, so doctors should use caution when ordering them and ensure the test they select is reliable. Overall, blood tests for Alzheimer’s have the potential to revolutionize diagnosis and improve patient outcomes, particularly for primary care physicians who often see patients with memory complaints.
Photo credit
www.nbcnews.com